Dr David Meya

He has been involved in clinical research of central nervous system infections and complications, with a focus on HIV Immune Reconstitution Inflammatory syndrome (IRIS), an often deadly complication of antiretroviral therapy (ART) in persons living with AIDS with opportunistic infections such as cryptococcal meningitis and tuberculosis. Dr. Meya has led epidemiological and translational research studies as well as randomized clinical trials in Uganda in collaboration with colleagues from the University of Minnesota.

Dr. Meya also has a specific interest in public health interventions to prevent meningitis at population level. He has advocated for cryptococcal antigen (CrAg) screening as a strategy to reduce deaths and hospitalizations from cryptococcal meningitis.  Dr. Meya continues to lead the efforts to initiate implementation of the national CrAg screening program in collaboration with the Ministry of Health, Clinton Health Access Initiative (CHAI), the Central public health laboratories and U.S. CDC.

Dr. Meya has been the Principal Investigator on NIH R01, CDC U01, and UK MRC grants and Industry-led research. Dr. Meya continues to be involved in advocacy to improve clinical care and outcomes in a predominantly HIV-infected patient population with limited resources for health.